Our Story

Alex is a Principal at Brandon’s Melbourne office working on investments in Australia, in the US, and in other international markets.

Previously, he was at Omega Funds in their Boston office, where he worked across therapeutic areas and with both preclinical and clinical stage companies. Alex served as a Board Observer at Scorpion Therapeutics (acquired by Lilly for $2.5bn), BridgeBio Oncology Therapeutics (NASDAQ: BBOT), and for NRG Therapeutics. Before Omega, Alex worked at Biogen in the Multiple Sclerosis Research Unit and at Putnam Associates, a life sciences specialist consultancy focused on drug pricing, access and reimbursement. Following a decade in Boston, Alex returned home to Melbourne in 2025.

Alex has a Bachelor of Biomedical Science (Degree with Honours) from The University of Melbourne, a PhD in Cancer Biology from The Walter and Eliza Hall Institute (The University of Melbourne), and a Graduate Certificate in Advanced Learning and Leadership from The University of Melbourne. Alex has authored peer-reviewed publications in journals including Blood, Cell, Frontiers in Neuroscience, Genes and Development, Journal of Experimental Medicine, and Nature Reviews Cancer.